The renin-angiotensin-aldosterone system: a specific target for hypertension management.
about
Overview of Antagonists Used for Determining the Mechanisms of Action Employed by Potential Vasodilators with Their Suggested Signaling PathwaysGenome-wide meta-analyses of plasma renin activity and concentration reveal association with the kininogen 1 and prekallikrein genesInorganic nitrite supplementation for healthy arterial agingCathepsin G activity lowers plasma LDL and reduces atherosclerosisSignificance of the transcription factor KLF5 in cardiovascular remodelingPhysiology of kidney reninRenin-Angiotensin-aldosterone system in diabetes and hypertensionThe application of Gaussian mixture models for signal quantification in MALDI-TOF mass spectrometry of peptidesAngiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records.Effects of ACE inhibition on proximal tubule sodium transport.Elevations of local intravascular pressures release vasoactive substances in humans.Angiotensin II stimulates trafficking of NHE3, NaPi2, and associated proteins into the proximal tubule microvilli.Gender specific association of RAS gene polymorphism with essential hypertension: a case-control studyOrphan nuclear receptor small heterodimer partner inhibits angiotensin II- stimulated PAI-1 expression in vascular smooth muscle cells.Hypertensive therapy: attacking the renin-angiotensin systemDevelopment and function of the human fetal adrenal cortex: a key component in the feto-placental unit.Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.EFFECT OF ASTRAGALOSIDE ON VITAMIN D-RECEPTOR EXPRESSION AFTER ENDOTHELIN-1-INDUCED CARDIOMYOCYTE INJURYThe past, present and future of renin-angiotensin aldosterone system inhibitionMarkers for progression of coronary disease.IL-1β and IL-18: inflammatory markers or mediators of hypertension?The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathwaysEvidence-based treatment of hypertension in patients with diabetes mellitus.24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.Rho kinase as a therapeutic target in cardiovascular disease.Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor.Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction.Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjectsAT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease.Managing high-risk patients with hypertension: focus on the renin-angiotensin system.Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon.Serum Soluble (Pro)Renin Receptor Levels in Maintenance Hemodialysis PatientsA system biology approach to understanding the molecular mechanisms of Gubentongluo decoction acting on IgA Nephropathy.Distinct effects of intravascular and extravascular angiotensin II on cerebrovascular circulation of newborn pigsProviding end-organ protection with renin-angiotensin system inhibition: the evidence so far.Associations of Renin-Angiotensin-Aldosterone System Genes With Blood Pressure Changes and Hypertension IncidenceDetection of metals and metalloproteins in the plasma of stroke patients by mass spectrometry methodsAngiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-κB pathways in human retinal pigment epithelium.Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway.
P2860
Q26752401-AF93994E-3878-4DC1-8BCE-334D5C8D7667Q26991686-90F6B02E-E34C-4D41-950E-3253451A5307Q27021840-FE9C437F-5D49-4115-94D4-32311C81F24BQ28245234-EB6F4D7B-CC7C-41A3-A129-63ABA0E1D92CQ28267393-90BAF24D-7B05-4DF7-A78F-CD09FBA1AE9CQ28279771-E9420EC9-16E3-45ED-86CD-073EA5145F7FQ28308222-CCD07AC4-B836-4376-9CE3-F1A52E5AE277Q28544751-C49D56BD-23D0-4CBF-9925-C677EC07802FQ31131489-9B17EB24-A2B1-471F-8966-0EC65E5EF1EEQ33226444-643B2259-E8DA-47AB-B13C-FB34CAA5795CQ33456585-79EA814B-DC6D-4309-B983-3C1895487859Q33589114-2D7874FF-F345-424E-BCF0-6395FA6E27FBQ33593956-AEFD3F6D-BB4F-410E-8182-40C3C46A2FBFQ33612309-399D5189-A60E-4952-93DB-583A394E5384Q33729203-9B778E5D-90DD-41E5-9976-549D7CB28B84Q33738624-5BF9F1EC-FABB-4960-818C-94B27370183CQ33783689-7253491E-626F-4720-AB14-02973671B1DCQ33800424-06E6F05C-8A4A-4C24-A41E-518D80408035Q34094354-0CF467E8-6A1B-4F11-8DB8-DFEA509D202DQ34371499-F6A9F94B-ABFF-48FA-9A0B-540A41F0C837Q34914125-88B55013-D683-4D42-A9EC-5366571F54E4Q35001942-57BAC1FC-95BC-47E7-881E-F9120A2D1509Q35040846-717F2388-A51A-42E6-A196-0A316E1FCEE7Q35050989-36D07F50-9B6D-41CB-8256-973C39F335FDQ35219694-1E258F46-C092-4250-AAFA-354891EB4207Q35352722-A4736A4A-6483-47E4-8950-5A459F959F36Q35686501-9A5AEEAD-D2E3-462C-9610-9336384716AFQ35799000-1F126099-0191-4C9A-BD24-304B8D7152F3Q35827907-7F0D6A49-ED7A-4675-982E-B7CFB6951999Q35837657-9329A470-72B6-4AEA-99D1-F72E13D013B6Q35886386-7A39ECE9-D72A-421E-BE8A-7F9A13493E0FQ35952223-A50AF9EE-8F44-4B4B-B810-E8AC9FF2EAEAQ36066002-051486D9-7FE2-4690-976B-61AC00D454F0Q36112117-13DEE9D6-F883-451C-BD4B-EE5D3B5F6C30Q36229368-96D12536-80E2-4B02-98CB-D50CCD334A0EQ36392674-8FA0DD4A-6907-4DF2-BAD7-9B269B1A8774Q36468860-4C24E4BD-4393-46C4-BB9E-F33DEA07A840Q36539409-1BCA0BAA-5396-4674-A78A-E93B849D4DA2Q36565868-D690AC46-B4A2-47A2-B3E9-437627DB0CBBQ36579769-41401AED-19DF-4E3D-AB1F-59348FC9A81F
P2860
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
@ast
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
@en
type
label
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
@ast
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
@en
prefLabel
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
@ast
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
@en
P1476
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
@en
P304
P356
10.1016/S0895-7061(99)00103-X
P433
P577
1999-12-01T00:00:00Z